The New Monolith | GenomeWeb

The New Monolith

Pfizer unveils what the company's structure will look like after it swallows up Wyeth. According to the Wall Street Journal, Pfizer will be splitting its research and development efforts in two: the small molecule section will be overseen by Pfizer's current R&D chief Martin Mackay, and the biologic section will be led by Wyeth's R&D chief Mikael Dolsten.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.